Marco Kessler

Marco Kessler has a diverse background in the pharmaceutical industry and academia. Marco started their career at Genome Therapeutics Corporation as a Senior Scientist, where they played a crucial role in discovering and validating novel targets for antifungal compounds. Marco also managed research collaborations and projects with Schering-Plough Corporation.

Afterward, Marco joined Ironwood Pharmaceuticals and held various positions, including Associate Director, Senior Principal Investigator, and Project Manager. In these roles, they contributed to the development and post-marketing requirements of the peptide drug, linaclotide. Marco successfully managed alliances with CROs, collaborations with academic researchers, and built relationships with key opinion leaders. Marco also played a significant part in the writing and filing of the NDA for linaclotide.

Additionally, Marco worked at Harvard University as an Adjunct Professor, where they shared their expertise with students.

Throughout their career, Marco demonstrated expertise in analytical pharmacology, drug metabolism pharmacokinetics, and assay development. Marco has a proven track record of successfully advancing preclinical discovery projects into development and clinical testing.

Marco Kessler has a Bachelor of Science degree in Biology-Chemistry, obtained from Elmira College, where they graduated Summa Cum Laude. Following this, they pursued a Doctor of Philosophy (PhD) degree in Biochemistry from Texas A&M University. Later, they embarked on Post-Doctoral Research Fellowships at Tufts University School of Medicine, specifically with the National Institutes of Health and The American Cancer Society, focusing on Molecular Biology.